Komori
General Meetings of Shareholders4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Convocation of the 2026 Annual General Meeting of Shareholders

The company announced that it would hold the 131st Annual General Meeting of Shareholders and submit matters concerning the disposition of surplus, the election of directors and directors serving as Audit and Supervisory Committee Members, and a shareholder proposal to amend the Articles of Incorporation. The number of candidates for directors who are not Audit and Supervisory Committee Members will decrease by 1, from the current 5 to 4.

Worth reading
80Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
1
reduction in the number of directors
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (131st)
2026
Jun 22
Date and time(Monday), 10:00 a.m. (reception opens at 9:00 a.m.)30 days from this disclosure to the meeting
Matters for resolution4 items (3 from the company, 1 from shareholders)
  1. Appropriation of surplus

  2. Election of 4 Directors (excluding Directors who are Audit and Supervisory Committee Members)

  3. Election of 1 director who is an Audit and Supervisory Committee Member

  4. Partial amendment to the Articles of Incorporation concerning the formulation of a medium-term management plan to enhance shareholder value

    Shareholder Proposal
Shareholder Proposal

The name of the individual or corporate proposer is Not disclosed. The proposal calls for the addition of a chapter and articles concerning the medium-term management plan as Proposal No. 4. The Board of Directors opposes the proposal.

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee5 candidates (4 under Proposal No. 2 and 1 under Proposal No. 3), including Not disclosed new appointments and 1 outside director
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (131st)
Date and time22 June 2026 (Monday), 10:00 a.m. (reception opens at 9:00 a.m.)
Matters for resolutionProposal 1: Appropriation of surplus, Proposal No. 2: Election of 4 Directors (excluding Directors who are Audit and Supervisory Committee Members), Proposal No. 3: Election of 1 director who is an Audit and Supervisory Committee Member, Proposal No. 4: Partial amendment to the Articles of Incorporation concerning the formulation of a medium-term management plan to enhance shareholder value
Shareholder ProposalThe name of the individual or corporate proposer is Not disclosed. The proposal calls for the addition of a chapter and articles concerning the medium-term management plan as Proposal No. 4. The Board of Directors opposes the proposal.
Director nominee5 candidates (4 under Proposal No. 2 and 1 under Proposal No. 3), including Not disclosed new appointments and 1 outside director
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Regarding directors who are not Audit and Supervisory Committee Members, the company explained that the number would be reduced by 1 "to improve the efficiency of the management structure." The company opposes the shareholder proposal on the grounds that the Board of Directors should flexibly determine the formulation and revision of the medium-term management plan and the selection of its performance indicators in light of the business environment. Requiring annual revisions in the Articles of Incorporation could be inconsistent with the business cycle and could lead to excessive emphasis on short-term performance.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2026 Annual General Meeting of Shareholders | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori